A new study compared all-cause health care costs and health resource utilization associated with first targeted therapies for advanced renal cell carcinoma.
The American Society of Clinical Oncology and the College of American Pathologists have updated their clinical practice guideline for HER2 testing in breast cancer to include five clinical recommendations related to ISH and IHC assays.
The National Comprehensive Cancer Network has released a new resource for liver, gallbladder, and bile duct cancers to assist patients in understanding their treatment decisions.

Transforming Possible Outcomes into Real Results


Shaji K Kumar, MD, explains the various considerations for management of multiple myeloma in different disease settings.
Subjective assessment of solid tumor response to therapy may misinform the intended benefit and limit the potential role of real-world evidence in value-based care research.
Long-term safety and efficacy data show that a CAR T-cell therapy produces high response rates in highly pretreated adult patients with relapsed or refractory DLBCL.
In a new study, researchers identified factors associated with high economic burden for patients with treated diffuse large B-cell lymphoma and follicular lymphoma.
A new diabetes blood test that analyzes glucose and HbA1c levels may alter the current diagnostic guidelines.
Houston Holmes, MD, MBA, FACP, Texas Oncology, discusses the barriers to accessing CAR-T therapy for patients in the community setting and reveals what to expect with the next wave of CAR-T products.